Published in Medical Devices and Surgical Technology Week, February 8th, 2004
The milestone was triggered by Allergan's selection of a collaboration compound for further development and commercialization.
"We are pleased to successfully achieve this phase of our collaboration with Acadia, which has generated an exciting new class of novel and selective muscarinic compounds," said Lester J. Kaplan, PhD, Allergan's president, research and development. "These drug candidates display a promising preclinical profile and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices and Surgical Technology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.